Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032601 | 0.84 | ALDH1A1 (0.40) | DRD2 | |
| SCHEMBL1899988 | 0.80 | ALDH1A1 (0.35) | DRD2CA12CA1CA9 | |
| SCHEMBL22032605 | 0.79 | KDM4E (0.46) | FBP1 | |
| SCHEMBL856992 | 0.78 | TRPA1 (0.41) | ALOX5APFEN1 | |
| SCHEMBL8503481 | 0.78 | GABRA1 (0.38) | DRD2HTR2AHTR2C | |
| SCHEMBL1178694 | 0.77 | SLC6A4 (0.38) | DRD2ALOX5APFEN1CA12CA1 | |
| SCHEMBL1056366 | 0.76 | ALOX5AP (0.36) | ALOX5APFEN1CA12CA1CA9 | |
| SCHEMBL9097154 | 0.76 | SLC6A4 (0.40) | ALOX5APFEN1HTR2AHTR2C | |
| SCHEMBL7714263 | 0.76 | ALOX5AP (0.34) | DRD2ALOX5APFEN1HTR2AHTR2C | |
| SCHEMBL17337274 | 0.76 | DRD2 (0.44) | DRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636650-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3097107-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-6369279-B1 | STYRENE WITH ETHER OR FLUORINE GROUPS FOR POLYMERS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | DRD2 4351/4885ALOX5AP 2103/4885FEN1 4639/4885 |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | DRD2 4351/4885ALOX5AP 2103/4885FEN1 4639/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | DRD2 4351/4885ALOX5AP 2103/4885FEN1 4639/4885 |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | DRD2 4351/4885ALOX5AP 2103/4885FEN1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.